EGFR and neoplasm: Furthermore, the CHP score was related to resistance against multiple anti-tumor drugs,e.g., mitosis and DNA replication inhibitors, whereas epidermal growth factor receptor (EGFR) pathway inhibitors were identified as potentially therapeutically beneficial for tumors with a high CHP score.